Skip to content

Study on the efficacy and safety of quercetin in the treatment of cognitive impairment in schizophrenia

Study on the efficacy and safety of quercetin in the treatment of cognitive impairment in schizophrenia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077965
Enrollment
Unknown
Registered
2023-11-24
Start date
2023-11-30
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

experimental group :Oral quercetin treatment 1000mg/day

Sponsors

Chaohu Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The diagnosis meets the diagnostic criteria for schizophrenia in the International Statistical Classification of Diseases and Related Health Problems, 11th edition (ICD-11); The condition is in remission; Age 18-60 years old; Educational level of primary school and above (=5 years of education); The patient and their family members understand the purpose of this study and agree to participate, and the patient and their family members sign an informed consent form.

Exclusion criteria

Exclusion criteria: Fulfilment of ICD-11 diagnostic criteria for other psychiatric disorders, e.g., depressive disorders, bipolar disorders, etc; Definite diagnosis of central nervous system diseases, such as stroke, craniocerebral trauma, Parkinson's disease, epilepsy, etc; Pregnant or breastfeeding women; all kinds of serious physical diseases, such as liver and kidney disease, cardiovascular disease, visual and auditory abnormalities; Those who have not obtained informed consent from themselves or their guardians.

Design outcomes

Primary

MeasureTime frame
snapshot;visual breadth;speech function;attention;delayed memory;

Secondary

MeasureTime frame
negative symptom;positive symptom;General psychopathological symptoms;

Countries

China

Contacts

Public ContactHuanzhong Liu

Chaohu Hospital of Anhui Medical University

huanzhongliu@ahmu.edu.cn+86 138 5515 2219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026